Monday, 14 June 2021

Interstitial cystitis (IC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030


Indication name: Interstitial cystitis (IC)

Interstitial cystitis (IC)/ bladder pain syndrome (BPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Litrature suggested that females are 9 times more likely to be diagnosed with IC/PBS compared to males, and the risk of IC/BPS increases with age. According to Thelansis prevalence ranges from 52-500/100,000 in females compared to 8-41/100,000 in males. The prevalence increases to 1,431/100,000 for females with first-degree relatives IC/PBS which suggests a hereditary component.

Competitive landscape of Interstitial cystitis (IC) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Interstitial cystitis (IC) Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

KOLs insights of Interstitial cystitis (IC) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Read more: Interstitial cystitis (IC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. No        Asset        Company                    Stage

1        LiRIS®        Allergan            Phase 2

2       2% sodium chondroitin sulfate        Watson Pharmaceuticals Phase 2

4        LP-08 80mg        Lipella Pharmaceuticals, Inc. Phase 2

5        TTI-1612        Trillium Therapeutics Inc. Phase 1

6        MN-001        MediciNova                Phase 2

7        Device: Uracyst        Stellar Pharmaceuticals Phase 3

8        ASP6294        Astellas Pharma Europe B.V.        Phase 2

9        PD 0299685        Pfizer                Phase 2

10        Adalimumab        ICStudy, LLC        Abbott        Phase 3

11        SI-722        Seikagaku Corporation Phase 2

12        AQX-1125         Aquinox Pharmaceuticals (Canada) Inc. Phase 3

13        Device: TC-3 Gel        UroGen Pharma Ltd. Phase 2

14        URG101        Urigen                Phase 2

15        Oxycodone naloxone DR Tabl Mundipharma Research  Phase 2

 

No comments:

Post a Comment

Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

  Indication name: Post-traumatic stress disorder (PTSD) Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market For...